Cadus Corporation, through its subsidiary, Cadus Technologies, Inc., focuses on licensing yeast-based and other drug discovery technologies to third parties. The company holds all patents, patent applications, know how, licenses and drug discovery technologies. Traditional Drug Discovery Drug discovery consists of three key elements: the target, such as a receptor, on which the drug would act, the potential drug candidates, which include organic chemicals, proteins or peptides, and the assays or tests to screen these compounds to determine their effect on the target. Yeast The company has developed technologies based on yeast that are useful in identifying drug discovery candidates targeted at G Protein-coupled receptors. Yeast is a single–celled microorganism that is commonly used to make bread, beer, and wine. Hybrid Yeast Cells The company developed a proprietary technology to insert human genes into yeast cells to create hybrid yeast cells. Its scientists typically created hybrid yeast cells by replacing yeast G Protein–coupled receptor genes and certain signaling molecules with their human equivalents. These hybrid yeast cells express a human G Protein–coupled receptor and a portion of its signaling pathway. These hybrid yeast cells can be used to identify those compounds that act as agonists or antagonists to that receptor or a molecule that is in its signaling pathway. The company designed and developed approximately 25,000 genetically different yeast strains that can be used to build novel hybrid yeast cells. Patents As of March 15, 2013, the subsidiary is the assignee of 23 issued U.S. patents and 2 related granted foreign patents covering aspects of its yeast technology and is the exclusive worldwide licensee of 2 issued U.S. patents and 1 related granted foreign patent for use in drug discovery. History The company was founded in 1992. It was incorporated in 1992, under the laws of the state of Delaware. The company was formerly known as Cadus Pharmaceutical Corporation and changed its name to Cadus Corporation in 2003.
cadus corp (KDUS:OTC BB)
767 Fifth Avenue
New York, NY 10153
|No competitor information is available for KDUS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CADUS CORP, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.